AML Vaccine Phase 3 Trial Succeeds with Memorial Sloan Kettering Cancer Center
What happened
Memorial Sloan Kettering Cancer Center and Sellas Life Sciences announced that their Phase 3 clinical trial for the vaccine galinpepimut-S succeeded. The vaccine, designed to treat acute myeloid leukemia, reduced the risk of death by 41% compared to other treatments in a trial involving 126 patients.
Why it matters
The vaccine targets acute myeloid leukemia, a deadly blood cancer that affects approximately 20,000 people annually in the United States. This successful trial marks a positive result in the development of new treatments for the disease.
Who's involved
- WT1Reported on the announcement of the vaccine trial success.
- Memorial Sloan Kettering Cancer CenterConducted the Phase 3 clinical trial for the leukemia vaccine.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Memorial Sloan Kettering Cancer CenterSpeculative
Memorial Sloan Kettering Cancer Center could see increased future funding access due to the validation of its research success.
Keep exploring
The entities involved
-
WT1
Nothing else this week.
-
Memorial Sloan Kettering Cancer Center
cancer treatment and research institution in New York City, United States